Editas Medicine (EDIT) Reports Q4 Loss of $1.00/sh

Editas Medicine (NASDAQ: EDIT) reported Q4 EPS of ($1.00), versus ($0.74) reported last year. Revenue for the quarter came in at $11.4 million, versus $12.3 million reported last year.

For earnings history and earnings-related data on Editas Medicine (EDIT) click here.

You May Also Be Interested In

• Guggenheim Upgrades Editas Medicine (EDIT) to Buy
• Cintas Corp. (CTAS) Tops Q1 EPS by 1c, Offers Guidance
• Scotiabank Reiterates Sector Outperform Rating on Ero Copper Corp. (ERO:CN) (ERO)